BR112012008111A2 - métodos e composições para tratamento de desordens fibróticas pulmonares - Google Patents

métodos e composições para tratamento de desordens fibróticas pulmonares

Info

Publication number
BR112012008111A2
BR112012008111A2 BR112012008111A BR112012008111A BR112012008111A2 BR 112012008111 A2 BR112012008111 A2 BR 112012008111A2 BR 112012008111 A BR112012008111 A BR 112012008111A BR 112012008111 A BR112012008111 A BR 112012008111A BR 112012008111 A2 BR112012008111 A2 BR 112012008111A2
Authority
BR
Brazil
Prior art keywords
methods
compositions
fibrotic disorders
pulmonary fibrotic
treating pulmonary
Prior art date
Application number
BR112012008111A
Other languages
English (en)
Inventor
Spangler Rhyannon
Smith Victoria
Original Assignee
Gilead Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Biologics Inc filed Critical Gilead Biologics Inc
Publication of BR112012008111A2 publication Critical patent/BR112012008111A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
    • A61K49/0047—Green fluorescent protein [GFP]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)

Abstract

métodos e composições para tratamento de desordens fibróticas pulmonares. são revelados neste pedido métods e composições para prevenir e tratar desordens fibróticas pulmonares, e para reduzir ou reverter os sintomas de desordens fibróticas pulmonares, tais como fibrose pulmonar idiopática. as composições incluem inibidores da proteína loxl2, e os métodos incluem métodos para produzir e usar os inibidores.
BR112012008111A 2009-08-21 2010-08-20 métodos e composições para tratamento de desordens fibróticas pulmonares BR112012008111A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23584609P 2009-08-21 2009-08-21
PCT/US2010/046244 WO2011022706A2 (en) 2009-08-21 2010-08-20 Methods and compositions for treatment of pulmonary fibrotic disorders

Publications (1)

Publication Number Publication Date
BR112012008111A2 true BR112012008111A2 (pt) 2017-02-21

Family

ID=43605534

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112012008080A BR112012008080A2 (pt) 2009-08-21 2010-08-20 ensaios de rastreamento in vivo.
BR112012008111A BR112012008111A2 (pt) 2009-08-21 2010-08-20 métodos e composições para tratamento de desordens fibróticas pulmonares

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112012008080A BR112012008080A2 (pt) 2009-08-21 2010-08-20 ensaios de rastreamento in vivo.

Country Status (15)

Country Link
US (1) US20110044981A1 (pt)
EP (2) EP2470218A4 (pt)
JP (3) JP2013502435A (pt)
KR (2) KR20120089274A (pt)
CN (2) CN102711820A (pt)
AU (2) AU2010283997B2 (pt)
BR (2) BR112012008080A2 (pt)
CA (2) CA2771786A1 (pt)
IL (2) IL218210A0 (pt)
MX (2) MX2012002269A (pt)
NZ (2) NZ625850A (pt)
RU (3) RU2012110580A (pt)
SG (1) SG178846A1 (pt)
WO (1) WO2011022706A2 (pt)
ZA (1) ZA201201290B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
US8679485B2 (en) 2007-08-02 2014-03-25 Gilead Biologics, Inc. Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
US9107935B2 (en) * 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
WO2011022670A1 (en) * 2009-08-21 2011-02-24 Arresto Biosciences, Inc In vivo screening assays
SG2014004816A (en) 2009-08-21 2014-03-28 Gilead Biologics Inc Catalytic domains from lysyl oxidase and loxl2
MX2012002271A (es) * 2009-08-21 2012-07-20 Gilead Biologics Inc Metodos y composiciones terapeuticas.
CA2775877A1 (en) * 2009-09-29 2011-04-07 Gilead Biologics, Inc. Methods and compositions for treatment of ocular fibrosis
RU2015108348A (ru) * 2010-02-04 2015-07-20 Джилид Байолоджикс, Инк. Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения
EP2714744A1 (en) * 2011-06-01 2014-04-09 Gilead Biologics, Inc. Lysyl oxidase-like 2 assay and methods of use thereof
CN107982531A (zh) * 2012-10-30 2018-05-04 吉利德科学公司 与赖氨酰氧化酶样蛋白2 (loxl2)相关的治疗和诊断方法
CA2901384A1 (en) * 2013-03-15 2014-09-18 Intermune, Inc. Proteomic ipf markers
WO2017152062A1 (en) 2016-03-04 2017-09-08 Gilead Sciences, Inc. Compositions and combinations of autotaxin inhibitors
US11660281B2 (en) 2017-06-29 2023-05-30 Yale University Compositions and methods of treating or preventing fibrotic lung diseases
US20210008020A1 (en) * 2018-03-12 2021-01-14 Yale University Methods of Treating or Preventing Acute Respiratory Distress Syndrome
CN110917351A (zh) * 2018-09-20 2020-03-27 华中科技大学同济医学院附属同济医院 Mbd2抑制剂在预防和治疗纤维化疾病中的用途
CN112138159B (zh) * 2019-06-28 2022-07-12 复旦大学 乳酸脱氢酶在组织炎症和纤维化治疗中的应用
WO2021015218A1 (ja) * 2019-07-24 2021-01-28 国立大学法人九州大学 転写関連因子を標的とする線維化疾患の予防または治療
AU2020353222A1 (en) * 2019-09-23 2022-04-14 Ecole Polytechnique Federale De Lausanne (Epfl) Treatment and prevention of aging related-disease and/or aging by the inhibition of sphingolipids

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) * 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3901654A (en) * 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3867517A (en) * 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) * 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3935074A (en) * 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US4034074A (en) * 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US4098876A (en) * 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
ATE8130T1 (de) * 1980-08-25 1984-07-15 Kabivitrum Ab Peptidsubstrate zum bestimmen der proteaseaktivitaet.
US5011771A (en) * 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) * 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
ATE45735T1 (de) * 1984-12-22 1989-09-15 Thomae Gmbh Dr K Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel.
US4627445A (en) * 1985-04-08 1986-12-09 Garid, Inc. Glucose medical monitoring system
US4801531A (en) * 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5182297A (en) * 1988-02-25 1993-01-26 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5021456A (en) * 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4943593A (en) * 1988-02-25 1990-07-24 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5120764A (en) * 1988-11-01 1992-06-09 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5192659A (en) * 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5641484A (en) * 1990-12-04 1997-06-24 Board Of Regents, The University Of Texas System Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
US6235887B1 (en) * 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
US5281521A (en) * 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US6015562A (en) * 1992-09-22 2000-01-18 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5721138A (en) * 1992-12-15 1998-02-24 Sandford University Apolipoprotein(A) promoter and regulatory sequence constructs and methods of use
MX336813B (es) * 1996-02-09 2016-02-02 Abbvie Biotechnology Ltd Anticuerpos humanos que ligan el tnfa humano.
DK0958495T3 (da) * 1997-02-06 2003-03-10 Therasense Inc In vitro analysand sensor med lille volumen
NZ515955A (en) * 1997-08-08 2003-04-29 Univ California Hybridoma producing a monoclonal antibody against beta-6 integrin
US6277622B1 (en) * 1997-08-11 2001-08-21 The University Of Sydney Synthetic polynucleotides
US6225118B1 (en) * 1997-10-01 2001-05-01 Biocure Limited Multicellular in vitro assay of angiogenesis
CA2308565A1 (en) * 1997-11-05 1999-05-14 Baylor College Of Medicine Sequences for targeting metastatic cells
US20020072089A1 (en) * 1999-11-23 2002-06-13 Holtzman Douglas A. Novel ITALY, Lor-2, STRIFE, TRASH, BDSF, LRSG, and STMST protein and nucleic acid molecules and uses therefor
US6140056A (en) * 1999-01-27 2000-10-31 Millennium Pharmaceuticals, Inc. MSP-18 protein and nucleic acid molecules and uses therefor
US6300092B1 (en) * 1999-01-27 2001-10-09 Millennium Pharmaceuticals Inc. Methods of use of a novel lysyl oxidase-related protein
US20040058355A1 (en) * 1998-09-30 2004-03-25 Millennium Pharmaceuticals, Inc. Novel 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, H1983, M1983, 38555 or 593 molecules and uses therefor
US6534261B1 (en) * 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US20030149997A1 (en) * 1999-02-19 2003-08-07 Hageman Gregory S. Diagnostics and therapeutics for arterial wall disruptive disorders
US20030152926A1 (en) * 1999-08-11 2003-08-14 Eos Biotechnology, Inc. Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
GB0001309D0 (en) * 2000-01-20 2000-03-08 Nestle Sa Valve arrangement
CA2405781A1 (en) * 2000-04-14 2001-10-25 Incyte Genomics, Inc. Secreted proteins
US7700359B2 (en) * 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
GB0014185D0 (en) * 2000-06-09 2000-08-02 Novartis Res Found Compound and method
US20030114410A1 (en) * 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
EP1354046B1 (en) * 2000-08-08 2007-06-06 Wyeth Regulation of expression of eer-7, a member of the lysyl oxidase gene family, by estrogen receptors
WO2003008647A2 (en) * 2000-11-28 2003-01-30 University Of Cincinnati Blood assessment of injury
US20040029114A1 (en) * 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
US20020182274A1 (en) * 2001-03-21 2002-12-05 Kung-Ming Lu Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract
US20030092037A1 (en) * 2001-07-18 2003-05-15 Osamu Matsuzaki Elk1 phosphorylation related gene
US20030129672A1 (en) * 2001-08-29 2003-07-10 Dyer Richard Dennis Method for identifying metalloenzyme inhibitors
WO2003035876A1 (de) * 2001-10-26 2003-05-01 Ribopharma Ag Verwendung einer doppelsträngigen ribonukleinsäure zur behandlung einer infektion mit einem (+)-strang-rna-virus
KR100450950B1 (ko) * 2001-11-29 2004-10-02 삼성전자주식회사 구내/공중망 무선 패킷데이터 서비스를 받는 이동단말기의 인증 방법 및 그 사설망 시스템
CA2470763A1 (en) * 2001-12-18 2003-06-26 Mondobiotech Laboratories Anstalt Novel pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases
US7186540B2 (en) * 2001-12-27 2007-03-06 National Institute of Advanced Indusrtial Science and Technology Thermostable glutaminase and thermostable glutaminase gene
US20060088532A1 (en) * 2002-03-07 2006-04-27 Kari Alitalo Lymphatic and blood endothelial cell genes
US7655397B2 (en) * 2002-04-25 2010-02-02 The United States Of America As Represented By The Department Of Health And Human Services Selections of genes and methods of using the same for diagnosis and for targeting the therapy of select cancers
AU2003263760A1 (en) * 2002-06-27 2004-01-19 The General Hospital Corporation Methods for the treatment or prevention of obesity
EP2236614A3 (en) * 2002-08-15 2011-01-26 Genzyme Corporation Brain endothelial cell expression patterns
US20050020521A1 (en) * 2002-09-25 2005-01-27 University Of Massachusetts In vivo gene silencing by chemically modified and stable siRNA
AU2003298873B2 (en) * 2002-12-06 2011-09-01 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
WO2004063355A2 (en) * 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
EP1603943A2 (en) * 2003-03-03 2005-12-14 Board of Regents, The University of Texas System Methods and compositions involving mda-7
EP2003196A3 (en) * 2003-06-09 2009-01-07 The Regents of the University of Michigan Compositions and methods for treating and diagnosing cancer
NZ575886A (en) * 2003-07-17 2010-11-26 Pacific Edge Biotechnology Ltd Serine or cysteine proteinase inhibitor clade H (SERPHINH1) as a marker for detection of gastric cancer
EP1670494A1 (en) * 2003-09-16 2006-06-21 Hadasit Medical Research Services & Development Ltd. Glatiramer acetate for use as an immuno-modulatory agent
US20070054278A1 (en) * 2003-11-18 2007-03-08 Applera Corporation Polymorphisms in nucleic acid molecules encoding human enzyme proteins, methods of detection and uses thereof
WO2005069975A2 (en) * 2004-01-23 2005-08-04 Massachusetts Eye & Ear Infirmary Lysyl oxidase-like 1 (loxl1) and elastogenesis
AU2005217623A1 (en) * 2004-02-24 2005-09-09 Attenuon Llp Inhibition of superoxide dismutase by tetrathiomolybdate: identification of new anti-angiogenic and antitumor agents
WO2006068829A1 (en) * 2004-12-21 2006-06-29 Alcon, Inc. Agents which regulate, inhibit, or modulate the activity and/or expression of lysyl oxidase (lox) and lox-like proteases as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
EP1869075B1 (en) * 2005-02-28 2012-04-11 Sangamo BioSciences, Inc. Anti-angiogenic methods and compositions
US20070021365A1 (en) * 2005-06-21 2007-01-25 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of Lysyl oxidase for treating tumor growth and diagnostics relating thereto
US20090035348A1 (en) * 2005-11-22 2009-02-05 Z & Z Medical Holdings, Inc. Dissolution of arterial plaque
US8445198B2 (en) * 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
UA96141C2 (ru) * 2005-12-09 2011-10-10 Юсиби Фарма, С.А. Нейтрализующее антитело, которое имеет специфичность к человеческому il-6
US8077896B2 (en) * 2006-12-12 2011-12-13 Sound Services, Llc Laser inclinometer audio direction
EP3666284A1 (en) * 2007-06-22 2020-06-17 Children's Medical Center, Corp. Methods and uses thereof of a fragment of saposin a
IL184627A0 (en) * 2007-07-15 2008-12-29 Technion Res & Dev Foundation Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue
US8679485B2 (en) * 2007-08-02 2014-03-25 Gilead Biologics, Inc. Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
US9107935B2 (en) * 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
WO2011022670A1 (en) * 2009-08-21 2011-02-24 Arresto Biosciences, Inc In vivo screening assays
MX2012002271A (es) * 2009-08-21 2012-07-20 Gilead Biologics Inc Metodos y composiciones terapeuticas.
SG2014004816A (en) * 2009-08-21 2014-03-28 Gilead Biologics Inc Catalytic domains from lysyl oxidase and loxl2
CA2775877A1 (en) * 2009-09-29 2011-04-07 Gilead Biologics, Inc. Methods and compositions for treatment of ocular fibrosis

Also Published As

Publication number Publication date
EP2470218A4 (en) 2013-04-03
JP2016029085A (ja) 2016-03-03
CA2771778A1 (en) 2011-02-24
KR20120089274A (ko) 2012-08-09
EP2467169A1 (en) 2012-06-27
IL218210A0 (en) 2012-04-30
WO2011022706A3 (en) 2011-04-14
SG178846A1 (en) 2012-04-27
JP2013502589A (ja) 2013-01-24
RU2012110580A (ru) 2013-09-27
IL218211A0 (en) 2012-04-30
RU2561672C2 (ru) 2015-08-27
MX2012002269A (es) 2012-07-20
AU2010284039A1 (en) 2012-03-22
CN102711839A (zh) 2012-10-03
KR20120054077A (ko) 2012-05-29
RU2012110578A (ru) 2013-09-27
BR112012008080A2 (pt) 2017-07-04
WO2011022706A2 (en) 2011-02-24
MX2012002270A (es) 2012-07-20
EP2467169A4 (en) 2013-01-02
AU2010283997A1 (en) 2012-03-22
NZ625850A (en) 2015-12-24
CN102711820A (zh) 2012-10-03
ZA201201290B (en) 2014-01-29
JP2013502435A (ja) 2013-01-24
NZ598464A (en) 2014-07-25
CA2771786A1 (en) 2011-02-24
RU2015124151A (ru) 2015-12-27
US20110044981A1 (en) 2011-02-24
EP2470218A2 (en) 2012-07-04
AU2010283997B2 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
BR112012008111A2 (pt) métodos e composições para tratamento de desordens fibróticas pulmonares
BR112017023315A2 (pt) polipeptídeos adequados para detergente
CY1119070T1 (el) Διαμορφωση της εκφρασης τρανσθυρετινης
AR090339A1 (es) Metodos de pronostico, diagnostico y tratamiento de la fibrosis pulmonar idiopatica
CY1120304T1 (el) Ενωσεις microrna και μεθοδοι για τη διαμορφωση της mir-21 δραστικοτητας
BR112016017564A8 (pt) métodos e composições para matar células senescentes e para tratar doenças e transtornos associados à senescência
BR112014012288A2 (pt) métodos para diagnosticar e tratar fibrose pulmonar idiopática
MX2016001315A (es) Variantes de enzimas.
BR112016016916A2 (pt) método de tratamento de angiodema hereditário (hae)
UY33826A (es) Proteínas de unión con dominios trivariables y sus usos
EA200970580A1 (ru) Таннат разагилина
WO2011127164A3 (en) Pharmaceutical compositions to treat fibrosis
DOP2009000196A (es) Inhibidores de la actividad de akt
DOP2010000368A (es) Inmunoglobulinas con dominio variable dual y usos de la misma
CR20120266A (es) Inmunoglobinas con dominio variable dual y usos de las mismas
MX2021001169A (es) Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas.
DOP2010000369A (es) Inmunoglobulinas con dominio variable dual y usos de la misma
DOP2011000333A (es) Inmunoglobulina con dominio variable dual y usos de la mismas
BR112013022813A2 (pt) diaminocarbonitrila pirimidinas e diaminocarboxamida substituída, composições das mesmas e métodos de tratamento com as mesmas
EA201101521A1 (ru) Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
MA33894B1 (fr) Procedes d'administration therapeutique de la pirferidone
WO2011138328A3 (en) Use of inhibitory molecules for the treatment of pulmonary hypertension
BR112015014876A2 (pt) composições e métodos para aperfeiçoar a solubilidade de rebaudiosídeo x
EA201200118A1 (ru) Дифференцировка мезенхемальных стволовых клеток
EA201490450A1 (ru) Новые ингибиторы ферментов

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]